Q3 2024 EPS Estimates for ANI Pharmaceuticals, Inc. Lifted by Capital One Financial (NASDAQ:ANIP)

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) - Equities research analysts at Capital One Financial increased their Q3 2024 EPS estimates for ANI Pharmaceuticals in a research note issued to investors on Thursday, September 19th. Capital One Financial analyst T. Chiang now anticipates that the specialty pharmaceutical company will post earnings per share of $0.75 for the quarter, up from their previous estimate of $0.74. The consensus estimate for ANI Pharmaceuticals' current full-year earnings is $3.50 per share.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share for the quarter, beating the consensus estimate of $0.95 by $0.07. ANI Pharmaceuticals had a return on equity of 15.64% and a net margin of 5.01%. The company had revenue of $138.00 million for the quarter, compared to the consensus estimate of $129.09 million. During the same period in the previous year, the business earned $1.06 earnings per share. ANI Pharmaceuticals's quarterly revenue was up 18.5% compared to the same quarter last year.

Other analysts also recently issued reports about the stock. StockNews.com downgraded shares of ANI Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Saturday, September 7th. Raymond James upped their price target on ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an "outperform" rating in a research note on Wednesday, September 18th. Truist Financial reaffirmed a "hold" rating and set a $60.00 price objective (down from $80.00) on shares of ANI Pharmaceuticals in a report on Wednesday, September 11th. Finally, HC Wainwright reissued a "buy" rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a report on Tuesday, September 17th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $78.80.

ANI Pharmaceuticals Stock Performance

NASDAQ ANIP traded up $0.42 on Monday, reaching $60.08. 477,572 shares of the stock were exchanged, compared to its average volume of 214,820. The company has a current ratio of 3.97, a quick ratio of 3.07 and a debt-to-equity ratio of 0.62. ANI Pharmaceuticals has a one year low of $48.20 and a one year high of $70.81. The firm has a market capitalization of $1.26 billion, a PE ratio of 37.29 and a beta of 0.71. The company's 50-day simple moving average is $61.07 and its two-hundred day simple moving average is $63.68.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of institutional investors have recently modified their holdings of the stock. Innealta Capital LLC bought a new stake in ANI Pharmaceuticals during the 2nd quarter valued at $65,000. Ridgewood Investments LLC bought a new stake in shares of ANI Pharmaceuticals in the second quarter valued at about $85,000. SG Americas Securities LLC purchased a new stake in ANI Pharmaceuticals in the first quarter worth about $106,000. ADAR1 Capital Management LLC bought a new position in ANI Pharmaceuticals during the 4th quarter worth about $132,000. Finally, Clear Street Markets LLC purchased a new position in ANI Pharmaceuticals during the 4th quarter valued at about $140,000. 76.05% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at ANI Pharmaceuticals

In related news, COO Muthusamy Shanmugam sold 14,257 shares of the firm's stock in a transaction on Wednesday, July 17th. The stock was sold at an average price of $63.16, for a total value of $900,472.12. Following the completion of the sale, the chief operating officer now directly owns 635,363 shares in the company, valued at $40,129,527.08. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other news, SVP Chad Gassert sold 20,000 shares of the company's stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $63.44, for a total value of $1,268,800.00. Following the transaction, the senior vice president now directly owns 193,226 shares in the company, valued at $12,258,257.44. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Muthusamy Shanmugam sold 14,257 shares of ANI Pharmaceuticals stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $63.16, for a total transaction of $900,472.12. Following the sale, the chief operating officer now owns 635,363 shares of the company's stock, valued at approximately $40,129,527.08. The disclosure for this sale can be found here. In the last 90 days, insiders sold 46,007 shares of company stock worth $2,911,790. 12.70% of the stock is currently owned by company insiders.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.